About Us
A Platform for Commercial Scientific Discovery
LIVERGENIX is set to become a leading platform built on a proprietary high-quality databank for the purpose of driving groundbreaking insights into liver and metabolic diseases. By integrating diverse data sources across Asia, LIVERGENIX provides unparalleled access to ground-truth biology, specifically through longitudinal clinical and omics data from rare to sourced liver specimens. This unique resource enables a deeper understanding of liver biology, accelerating clinically driven discoveries and the development of precision medicine for liver disease treatment.
Our Team
THE EXPERTS YOU CAN TRUST
Donna See
Executive Chair
Donna See is a seasoned biotech leader with 20+ years of experience driving scientific innovation to commercial success. She has led and scaled high-impact ventures, including TARA Biosystems and Vixen Pharmaceuticals, which was acquired by Eli Lilly and commercialized as Olumiant®. Previously, she spearheaded commercialization at Columbia Technology Ventures, managing 2,000+ assets.
Cheng Han Ng
CEO
Asst. Professor Cheng Han Ng, a distinguished Yong Loo Lin School of Medicine alumnus (Class of 2023), is a leading expert in MASH with 200+ publications. Named a Stanford Top 2% Scientist, he also serves as a visiting professor at Kurume University and Yokohama City University, advancing research in metabolic disease.
Nicholas Syn
CTO
Dr. Nicholas Syn is the inaugural Dean’s Fellow and an Assistant Professor (Adjunct) at the Yong Loo Lin School of Medicine, National University of Singapore. Dr Syn has published over 300 papers, including in top journals, and was named among the World’s Top 2% of Scientists ranking published by Stanford University and Elsevier for three consecutive years based on calendar year citations in 2022, 2023 and 2024.
Mark Dinesh Muthiah
CSO
Adj. Associate Prof. Mark D. Muthiah, senior consultant and medical director at National University Hospital, Singapore, is a renowned expert in Gastroenterology and Hepatology specializing in MASH. With 170+ publications and training under Prof. Arun J. Sanyal, he is a key global speaker and a valuable asset for liver disease research.
Contact Info
Let’s Connect!
Curious about our AI-driven biomarker discovery, precision diagnostics, or partnership opportunities? Contact us to explore collaborations or learn more about how Livergenix is transforming liver disease treatment.